The CirCLIQ Injector approval for subcutaneous isatuximab in multiple myeloma is the first anticancer treatment delivered via an on-body injector in Japan.
|Videos|December 14, 2017
Dr. Chari on Challenges in Sequencing Agents for Multiple Myeloma
Author(s)Ajai Chari, MD, PhD
Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses challenges in sequencing agents for patients with multiple myeloma.
Advertisement
Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses challenges in sequencing agents for patients with multiple myeloma.
According to Chari, the use of daratumumab (Darzalex) induction therapy and ixazomib (Ninlaro) in the maintenance setting are making patients refractory to a different drug class.
Many researchers are investigating how quickly chimeric antigen receptor (CAR) T-cell therapy can be given to patients based on the risk value, explains Chari.
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
The CHMP opinion is backed by phase 3 MonumenTAL-3 data evaluating talquetamab plus daratumumab in relapsed/refractory multiple myeloma.
The top 5 OncLive TV videos of the week.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Iberdomide plus daratumumab/dexamethasone improved PFS vs DVd in relapsed/refractory multiple myeloma, meeting a dual primary end point of EXCALIBER-RRMM.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
3
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
4
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
5